September 14, 2021- Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs.
September 15, 2021- Dr. Foley will lead all medical activities for Sera as the company executes its vision to be the Pregnancy Company.
September 13, 2021- Sera will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on Tuesday, September 21, 2021 at 8:15 a.m. Eastern Time.
August 17, 2021- Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare
July 14, 2021 - Sera today announced the pricing of its initial public offering of 4,687,500 shares of its common stock at a price to the public of $16.00 per share.